Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elucirem (gadopiclenol) vs Dotarem (gadoteric acid) in DSC-MRI perfusion of brain gliomas
2022-002720-12Phase 3Completed
- Sponsor
- Guerbet
- Start
- Jan 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gadopiclenol in brain glioma and glioma (2 arms), sponsored by Guerbet. Primary endpoint: Primary image quality endpoint (off-site readers). Started Jan 2023; status: completed.
02
Drugs
gadopiclenol
03
Conditions
brain gliomaglioma
Beyond the preview
Go deeper on 2022-002720-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002720-12.